SLAS Discovery

Scope & Guideline

Empowering Innovation in Analytical Chemistry

Introduction

Explore the comprehensive scope of SLAS Discovery through our detailed guidelines, including its aims and scope. Stay updated with trending and emerging topics, and delve into declining areas to understand shifts in academic interest. Our guidelines also showcase highly cited topics, featuring influential research making a significant impact. Additionally, discover the latest published papers and those with high citation counts, offering a snapshot of current scholarly conversations. Use these guidelines to explore SLAS Discovery in depth and align your research initiatives with current academic trends.
LanguageEnglish
ISSN2472-5552
PublisherELSEVIER SCIENCE INC
Support Open AccessYes
CountryUnited States
TypeJournal
Convergefrom 2017 to 2024
AbbreviationSLAS DISCOV / SLAS Discov.
Frequency10 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressSTE 800, 230 PARK AVE, NEW YORK, NY 10169

Aims and Scopes

SLAS Discovery focuses on innovative methodologies and technologies that drive drug discovery and development, particularly emphasizing high-throughput screening (HTS) and its applications across various therapeutic areas.
  1. High-Throughput Screening (HTS):
    The journal extensively covers the development and optimization of high-throughput screening methodologies for drug discovery, enabling rapid evaluation of large compound libraries against biological targets.
  2. Cell-Based Assays and Imaging:
    SLAS Discovery emphasizes the use of cell-based assays, including high-content imaging and 3D cell cultures, to better mimic in vivo conditions and enhance the relevance of screening results.
  3. Target Identification and Validation:
    Research published in the journal often focuses on novel strategies for target identification and validation, including the application of proteomics and genomics to discover new drug targets.
  4. Automation and Robotics in Drug Discovery:
    The journal highlights advancements in automation and robotics that facilitate efficient assay development and compound screening, improving reproducibility and data quality in drug discovery.
  5. Phenotypic Screening:
    SLAS Discovery also explores phenotypic screening approaches that assess biological responses to compounds in cellular models, offering insights into complex drug action mechanisms.
  6. Emerging Technologies:
    The journal is dedicated to showcasing emerging technologies such as artificial intelligence (AI) and machine learning (ML) in drug discovery, aiming to enhance data analysis and predictive capabilities.
The landscape of drug discovery is rapidly changing, and SLAS Discovery reflects this evolution through an increasing focus on several key emerging themes.
  1. COVID-19 Therapeutics:
    A significant number of recent publications are dedicated to discovering and validating therapeutics for COVID-19, reflecting the urgent need for effective treatments and the journal's responsiveness to global health challenges.
  2. 3D Cell Culture and Organoids:
    There is a growing trend towards the use of 3D cell culture systems and organoids, which provide more accurate representations of human tissues, enhancing drug screening and development processes.
  3. Artificial Intelligence and Machine Learning:
    The integration of AI and machine learning techniques into drug discovery processes is on the rise, with studies focusing on data mining, predictive modeling, and automated analysis to streamline hit identification.
  4. Targeted Protein Degradation:
    Research on targeted protein degradation, particularly using PROTACs (Proteolysis Targeting Chimeras), is emerging as a significant area of interest, offering new strategies for drug discovery against challenging targets.
  5. Synergistic Drug Combinations:
    There is an increasing focus on identifying synergistic drug combinations to enhance therapeutic efficacy, particularly in cancer treatment, which reflects a shift towards personalized medicine approaches.

Declining or Waning

While SLAS Discovery continues to evolve, certain themes are becoming less prominent in recent publications, indicating a shift in focus within the field.
  1. Traditional Biochemical Assays:
    There is a noticeable decline in publications focusing solely on traditional biochemical assays, as the field moves towards more complex and physiologically relevant models.
  2. Single-Dimensional Drug Screening:
    Research centered around single-dimensional drug screening methods is waning, with a shift towards more integrated and multi-parametric approaches that provide a broader understanding of drug effects.
  3. Basic Pharmacology Studies:
    Basic pharmacology studies that do not incorporate advanced technologies or high-throughput capabilities appear to be less frequent, as there is a growing emphasis on translational research and clinical relevance.
  4. In Vitro Models Lacking Complexity:
    The use of simplistic in vitro models is decreasing, as researchers prioritize more complex systems that better replicate human physiology, such as organoids and multi-cellular models.
  5. Focus on Established Targets:
    There is a reduction in studies targeting well-characterized pathways or proteins, as the field increasingly seeks novel targets and mechanisms of action to overcome drug resistance.

Similar Journals

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Empowering Drug Discovery with Cutting-Edge Design Techniques
Publisher: SPRINGERISSN: 0920-654XFrequency: 12 issues/year

JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN, published by Springer, serves as a premier platform for researchers in the fields of computer science applications, drug discovery, and physical and theoretical chemistry. Since its inception in 1987, the journal has played a pivotal role in advancing the methodologies and technologies used in molecular design and screening. With an impressive impact factor and a ranking within the top quartile across related disciplines, this journal offers invaluable insights and innovative approaches that are essential for scholars and practitioners in these dynamic fields. The journal's rigorous peer-review process ensures high-quality publications that contribute significantly to both theoretical and practical advancements. Though it operates under a subscription model, the journal remains dedicated to fostering knowledge dissemination and collaboration among researchers.

MedComm

Fostering Collaboration in Cutting-Edge Medical Research
Publisher: WILEYISSN: Frequency: 4 issues/year

MedComm is a distinguished Open Access journal published by Wiley, located in the United States. Since its inception in 2020, it has rapidly established itself as a leading platform for cutting-edge research in the fields of Biochemistry, Cell Biology, Drug Discovery, Genetics, Immunology and Allergy, and Oncology, achieving a prestigious Q1 category ranking across multiple disciplines in 2023. MedComm is committed to providing a rigorous and transparent peer-review process, ensuring the publication of high-quality articles that advance the frontiers of medical science. With its remarkable Scopus ranking, the journal serves as an invaluable resource for researchers, professionals, and students looking to stay abreast of important developments in the life sciences. The open access model facilitates widespread dissemination of scholarly work, fostering collaboration and innovation within the global scientific community. Researchers interested in submitting their work or exploring the latest findings are encouraged to engage with this pivotal journal during the converged years from 2020 to 2024.

CELL BIOCHEMISTRY AND BIOPHYSICS

Pioneering Research in Cellular Mechanisms
Publisher: HUMANA PRESS INCISSN: 1085-9195Frequency: 4 issues/year

CELL BIOCHEMISTRY AND BIOPHYSICS is a distinguished journal published by HUMANA PRESS INC, focusing on critical advancements in the fields of biochemistry, biophysics, and cell biology. Since its establishment, the journal has provided a robust platform for the dissemination of cutting-edge research, covering diverse aspects of cellular biochemistry and the physical principles that underlie biological systems. With an emphasis on interdisciplinary studies, the journal aims to facilitate knowledge exchange among researchers, professionals, and students from various scientific backgrounds. As reflected in its 2023 category rankings, it holds a respectable position in Q3 for Biochemistry and Cell Biology, and Q2 for both Biophysics and Medicine (miscellaneous), indicating its significant contribution to these fields. Although it operates under a subscription model, the journal's commitment to maintaining high publication standards ensures that only impactful studies are shared with its audience. With a range of articles spanning theoretical insights to practical applications, CELL BIOCHEMISTRY AND BIOPHYSICS is an essential resource for those aiming to stay at the forefront of biochemical and biophysical research.

Drug Metabolism and Pharmacokinetics

Transforming Pharmacological Knowledge into Practice
Publisher: JAPANESE SOC STUDY XENOBIOTICSISSN: 1347-4367Frequency: 6 issues/year

Drug Metabolism and Pharmacokinetics is a premier academic journal committed to advancing the understanding of drug metabolism processes and pharmacokinetic principles critical to the development of therapeutics. Published by the Japanese Society for the Study of Xenobiotics, this journal has established itself as a vital resource within Pharmaceutical Science and Pharmacology, achieving a respectable Q2 ranking in the latest 2023 metrics. Spanning from 2002 to 2024, the journal publishes original research articles, reviews, and insights that address contemporary issues in xenobiotic metabolism and pharmacologic practices. With its ISSN of 1347-4367 and E-ISSN of 1880-0920, Drug Metabolism and Pharmacokinetics is indexed in leading databases, enhancing its visibility and accessibility for researchers, professionals, and students alike. By fostering a rigorous scientific dialogue, the journal plays an essential role in shaping the future of pharmacology and pharmaceutical sciences.

Current Computer-Aided Drug Design

Empowering Researchers with Insights in Computer-Aided Drug Development
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1573-4099Frequency: 4 issues/year

Current Computer-Aided Drug Design, published by BENTHAM SCIENCE PUBL LTD, is a pivotal journal dedicated to the integration of computer-aided methodologies within the drug design process. With its ISSN 1573-4099 and E-ISSN 1875-6697, this journal serves as a vital resource for researchers, professionals, and students interested in advancing the fields of pharmacology and molecular medicine. Operating under a framework that spans from 2006 to 2024, it aims to foster innovative approaches and discussions surrounding drug design strategies, computational techniques, and the therapeutic potential of novel compounds. Although it currently holds a Q4 rating in Drug Discovery and Molecular Medicine as well as a Q3 in Medicine (miscellaneous) within the 2023 category quartiles, the journal continues to enhance its visibility and relevance in the academic community. Its Scopus rankings reflect its commitment to quality research, positioning it in the context of drug discovery and molecular studies. As the field of drug design evolves, Current Computer-Aided Drug Design remains an essential platform for disseminating cutting-edge findings and facilitating collaboration among specialists aiming for significant advancements in drug development.

CURRENT DRUG TARGETS

Navigating the Landscape of Pharmacology
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1389-4501Frequency: 16 issues/year

CURRENT DRUG TARGETS is a leading peer-reviewed journal dedicated to advancements in the fields of Clinical Biochemistry, Drug Discovery, Molecular Medicine, and Pharmacology. Published by Bentham Science Publishers Ltd, this esteemed journal has solidified its position in the academic community with a 2023 Q2 ranking in several categories, highlighting its influence and relevance in drug research and development. With an ISSN of 1389-4501 and E-ISSN 1873-5592, CURRENT DRUG TARGETS facilitates the dissemination of high-quality articles that explore novel therapeutic strategies and drug design principles. Catered to researchers, professionals, and students, the journal has a commitment to advancing knowledge while addressing contemporary challenges in pharmacological sciences. As it converges from 2000 to 2024, CURRENT DRUG TARGETS remains a vital resource in understanding the complexities of drug action and interaction, making it indispensable for anyone pursuing cutting-edge research in related disciplines.

Letters in Drug Design & Discovery

Exploring New Horizons in Molecular Medicine
Publisher: BENTHAM SCIENCE PUBL LTDISSN: 1570-1808Frequency: 12 issues/year

Letters in Drug Design & Discovery is an esteemed journal dedicated to advancing the fields of Drug Discovery and Molecular Medicine. Published by Bentham Science Publishers, this journal offers a platform for the dissemination of innovative research and advanced methodologies, enhancing collaboration among researchers and professionals in pharmaceutical sciences. Despite its current Q4 ranking in Drug Discovery and Molecular Medicine and Q3 in Pharmaceutical Science for 2023, the journal is committed to improving its presence in the academic community by providing quality, peer-reviewed publications that cover various aspects of drug design and discovery, including novel therapeutic approaches and methodologies. With a focus on both foundational and cutting-edge research from around the globe, Letters in Drug Design & Discovery is pivotal for those seeking to stay abreast of developments in drug development and molecular research. Researchers are encouraged to submit their work, engage with the burgeoning field, and contribute to the ongoing dialogue driven by this journal, which spans the years from 2005 to 2024. While the journal does not currently offer open access, its contributions remain accessible to a wide range of academic and professional audiences.

MOLECULAR AND CELLULAR PROBES

Fostering Innovation in Biochemistry and Genetics
Publisher: ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTDISSN: 0890-8508Frequency: 6 issues/year

MOLECULAR AND CELLULAR PROBES, published by Academic Press Ltd - Elsevier Science Ltd, stands as a prominent journal at the intersection of cell and molecular biology. With an ISSN of 0890-8508 and an E-ISSN of 1096-1194, this journal has consistently contributed to the scientific discourse since its inception in 1987, converging its scholarly content through to 2024. As a member of Q3 in both Cell Biology and Molecular Biology categories, it provides a platform for innovative research and critical insights into cellular mechanisms, signaling pathways, and molecular interactions. Its Scopus rankings position it within the top half of its categories, fostering a vibrant academic community that supports the exploration and advancement of biochemistry, genetics, and molecular biology. Although it does not currently offer Open Access, the high-quality peer-reviewed articles published in MOLECULAR AND CELLULAR PROBES are invaluable resources for researchers, professionals, and students who seek to stay at the forefront of breakthroughs in these essential fields.

Journal of Cheminformatics

Exploring innovative solutions in cheminformatics.
Publisher: BMCISSN: 1758-2946Frequency: 1 issue/year

Journal of Cheminformatics, published by BMC, is a premier open-access journal that has been a cornerstone of cheminformatics research since its inception in 2009. With an ISSN of 1758-2946, this journal operates from the heart of the United Kingdom, providing a dynamic platform for disseminating high-quality, peer-reviewed articles that explore the integration of computer science with chemistry. The journal proudly stands in the prestigious Q1 category across multiple disciplines, including Computer Graphics, Computer-Aided Design, and Library and Information Sciences, showcasing its exceptional impact in the fields of cheminformatics and computational chemistry. Additionally, it ranks impressively in various Scopus categories, with notable placements such as #7 in Library and Information Sciences and #15 in Physical and Theoretical Chemistry, demonstrating its significance to the academic community. As a leader in open-access publishing, the Journal of Cheminformatics ensures that cutting-edge research and innovations are freely accessible to researchers, professionals, and students alike, fostering collaboration and advancement in this rapidly evolving field.

NATURAL PRODUCT RESEARCH

Pioneering Discoveries in Plant and Organic Chemistry
Publisher: TAYLOR & FRANCIS LTDISSN: 1478-6419Frequency: 24 issues/year

NATURAL PRODUCT RESEARCH is a distinguished journal published by Taylor & Francis Ltd, dedicated to advancing the field of natural product science through the dissemination of high-quality research. Established in 2003, this journal serves as a pivotal platform for scholars in Analytical Chemistry, Biochemistry, Organic Chemistry, and Plant Science, boasting an impressive categorization including Q2 in Plant Science and Q3 in the other disciplines for 2023. With a current Scopus ranking that highlights its significance within various scientific communities, NATURAL PRODUCT RESEARCH reflects the complexities and innovations associated with natural compounds and their applications. Researchers, professionals, and students will find valuable insights and breakthroughs that contribute to the understanding of bioactive compounds and their roles in health and environmental sustainability. Access options are available, ensuring that the latest findings are accessible to a global audience. As this journal continues to publish until 2024, it remains an essential resource for those at the forefront of natural product research.